MLYS Stock Forecast: Mineralys Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$14
−3.53% on the day

The median 12-month analyst price target for Mineralys Therapeutics, Inc. is $52. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.2B
Ticker Nerd rank
13/ 100
Median analyst target
$52
Analysts covering
11
Revenue$0.0
Operating income−$246.0M
Net income−$241.1M
Free cash flow−$32.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.9%
1M
−36.7%
YTD
−62.4%
1Y
−67.4%
From 52W high
−68.5%
From 52W low
0.0%
$14
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Mineralys Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
13/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
64
Value
51
Quality
45
Volatility
40
Revisions
23
Momentum
21
Growth
16
Issuance
10

Accruals (64): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MLYS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLYS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26MLYSHigh $56Median $52Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9
Buy
2
Hold
0
Sell
$19
Low
$52
Median
$56
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026HC Wainwright & Co.ReiteratesBuy$56
12 Oct 2026UBSInitiatesNeutral$29
27 Apr 2026TD CowenInitiatesBuy—
13 Mar 2026B of A SecuritiesMaintainsBuy—
19 Dec 2025StifelMaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025Wells FargoMaintainsOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025Wells FargoMaintainsOverweight—
9 Sept 2025Goldman SachsMaintainsBuy—
8 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025JefferiesMaintainsHold—
28 Aug 2025B of A SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025JefferiesInitiatesHold—
13 May 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025HC Wainwright & Co.MaintainsBuy—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MLYS.

Market Radar

This page is one stock. Monday covers all of them.

MLYS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MLYS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Mineralys Therapeutics, Inc. returned −67.4% against +6.9% for the S&P 500, dividends included.

MLYS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26MLYSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLYS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.4×

Cheaper than 37% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−68.5%

Higher than 18% of US stocks

Return on assets
−39.6%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mineralys Therapeutics, Inc. has a market value of $1.2B and an enterprise value of $683.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$349.6M.

  • Diluted earnings per share, trailing twelve months: −$4.24.

  • Free cash flow in the twelve months to 30 June 2026: −$138.8M.

  • Shares outstanding: 88.4M.

  • Mineralys Therapeutics, Inc. employs 76 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

MLYS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MLYSMineralys Therapeutics, Inc.$1.2B13
GHRSGH Research Plc$1.2B62
GENBGenerate Biomedicines, Inc.$1.2B0
TSHATaysha Gene Therapies, Inc.$1.2B56
MNKDMannKind Corp.$1.2B41
OCULOcular Therapeutix, Inc.$1.2B20
NVAXNovavax, Inc.$1.2B66

Take a look at MLYS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Mineralys Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MLYS

What is the MLYS stock price forecast for 2026-2027?

The median 12-month analyst price target for Mineralys Therapeutics, Inc. is $52, with estimates ranging from $19 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLYS stock a buy right now?

Of the 11 analysts covering Mineralys Therapeutics, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mineralys Therapeutics, Inc. 13 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLYS?

As at 21 Nov 2026, Mineralys Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (64 of 100).

Will MLYS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts is $52, and Ticker Nerd's factor model ranks Mineralys Therapeutics, Inc. 13 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLYS stock forecast for 2030?

No analyst covering Mineralys Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $56 over the next 12 months.

How has MLYS stock performed over the past year?

Mineralys Therapeutics, Inc. returned -67.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mineralys Therapeutics, Inc. do?

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Company

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.

CEO Dr. Jon Congleton · 76 employees · United States · https://mineralystx.com